Landscape Capital Management L.L.C. Takes $227,000 Position in Solventum Co. (NYSE:SOLV)

Landscape Capital Management L.L.C. bought a new stake in Solventum Co. (NYSE:SOLV) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,258 shares of the company’s stock, valued at approximately $227,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Intech Investment Management LLC acquired a new stake in shares of Solventum in the third quarter valued at $317,000. Cornerstone Advisors LLC increased its stake in shares of Solventum by 33.0% in the third quarter. Cornerstone Advisors LLC now owns 3,625 shares of the company’s stock valued at $253,000 after buying an additional 900 shares in the last quarter. Ontario Teachers Pension Plan Board acquired a new stake in shares of Solventum in the third quarter valued at $1,742,000. First Horizon Advisors Inc. increased its stake in shares of Solventum by 42.6% in the third quarter. First Horizon Advisors Inc. now owns 1,572 shares of the company’s stock valued at $110,000 after buying an additional 470 shares in the last quarter. Finally, Howe & Rusling Inc. acquired a new stake in shares of Solventum in the third quarter valued at $234,000.

Solventum Trading Up 1.1 %

Shares of SOLV opened at $71.58 on Tuesday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05. The stock’s 50-day moving average price is $70.52 and its two-hundred day moving average price is $62.35.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Morgan Stanley raised their price target on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Wolfe Research assumed coverage on Solventum in a report on Thursday, September 26th. They issued a “peer perform” rating on the stock. Stifel Nicolaus assumed coverage on Solventum in a report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price target on the stock. BTIG Research assumed coverage on Solventum in a report on Thursday, September 5th. They issued a “neutral” rating on the stock. Finally, Wells Fargo & Company decreased their price target on Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, Solventum currently has an average rating of “Hold” and a consensus price target of $68.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.